<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01241695</url>
  </required_header>
  <id_info>
    <org_study_id>GCOS-002-CFS</org_study_id>
    <nct_id>NCT01241695</nct_id>
  </id_info>
  <brief_title>Safety, Acceptability and Efficacy of a Long-term Intervention With a Diabetes-specific Low-carbohydrate, High-mono-unsaturated Fatty Acid Containing Oral Nutritional Supplement on Glycaemic Control in Type 2 Diabetic Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Kabi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the safety, acceptability and the efficacy of a
      12-week intervention with a diabetes-specific oral nutritional supplement on glycaemic
      control in type 2 diabetic patients with or at risk of malnutrition
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postprandial blood glucose (iAUC) (0-240 min)</measure>
    <time_frame>day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>postprandial blood glucose (iAUC) (0-240 min)</measure>
    <time_frame>day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>postprandial blood glucose (iAUC) (0-240 min)</measure>
    <time_frame>day 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>postprandial peak blood glucose (0-240 min)</measure>
    <time_frame>day 1, day 42, day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postprandial triglycerides (0-240 min)</measure>
    <time_frame>day 1, day 42, day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total cholesterol, HDL-cholesterol, LDL-cholesterol</measure>
    <time_frame>day 1, day 42, day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total protein, albumin, prealbumin</measure>
    <time_frame>day 1, day 42, day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c, HOMA-IR index</measure>
    <time_frame>day 1, day 42, day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>c-peptide</measure>
    <time_frame>day 1, day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gastrointestinal tolerance</measure>
    <time_frame>week 1, week 6, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>palatability / taste test</measure>
    <time_frame>week 1, week 6, week 12</time_frame>
    <description>by means of a sensorial questionnaire the patients will evaluate the overall liking, appearance, smell, taste, mouth feel et cetera of the study nutrition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily compliance</measure>
    <time_frame>day 1-84</time_frame>
    <description>in a daily compliance questionnaire the patients record the amount of oral nutritional supplements consumed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diben DRINK (200 ml) / a diabetes-specific oral nutritional supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fresubin(R) energy fibre DRINK / an isoenergetic standard oral nutritional supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral nutritional supplement, food for special medical purposes</intervention_name>
    <description>2 servings of 200 ml per day, treatment period: 12 weeks</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral nutritional supplement, food for special medical purposes</intervention_name>
    <description>2 servings of 200 ml per day, treatment period: 12 weeks</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of type 2 diabetes according to the WHO diagnostic criteria for more than 6
             months: Fasting plasma glucose (FPG) ≥ 126 mg/dl (7.0 mmol/l) or 2-h plasma glucose ≥
             200 mg/dl (11.1 mmol/l) during an OGTT (oral glucose tolerance test);

          -  HbA1c between 6.5-8.5 % (confirmed in the previous 3 months),

          -  capable of using oral nutritional supplementation,

          -  on stable and controlled anti-diabetic regime for at least 1 months,

          -  use of metformin and/or sulphonylureas as oral anti-diabetic medication,

          -  in need of nutritional support because of ≥5% involuntary weight loss in the last 3
             months, ≥10% involuntary weight loss in the last 6 months, inadequate nutritional
             intake causing failure to meet nutritional requirements or at risk of developing
             malnutrition

        Exclusion Criteria:

          -  diabetes type 1,

          -  participation in a clinical trial with an investigational product or regular use of
             disease-specific oral nutritional supplements within 4 weeks prior to study start

          -  patients requiring a fibre free diet,

          -  enteral tube feed or parenteral nutrition,

          -  concomitant therapy with systemic glucocorticoids, insulins or anti-diabetic
             medication other than metformin and sulphonylureas,

          -  known or suspected intolerance or allergy to any component of the investigational
             product(s),

          -  any acute gastrointestinal disease within 2 weeks prior to study entry,

          -  gastrectomy, gastroparesis or other gastric emptying abnormalities,

          -  acute sever heart failure (NYHA class 4), liver insufficiency / failure (male: ALAT &gt;
             150 U/l; female: ALAT &gt; 120 U/l) or renal failure requiring dialysis,

          -  cancer cachexia,

          -  galactosaemia, fructosaemia,

          -  suspicion of drug abuse, abuse of/addiction to alcohol,

          -  pregnant or breast feeding women, or fertile women refusing to use contraceptives,

          -  patients with untreated major psychiatric disorder,

          -  known HIV positive (safety reasons),

          -  patient unable to co-operate adequately
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Mayr, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Practice, 78333 Stockach</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Practice</name>
      <address>
        <city>Stockach</city>
        <state>Baden-Württemberg</state>
        <zip>78333</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2010</study_first_submitted>
  <study_first_submitted_qc>November 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2010</study_first_posted>
  <last_update_submitted>June 29, 2012</last_update_submitted>
  <last_update_submitted_qc>June 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral nutritional supplement, diabetes mellitus type 2, glycaemic control</keyword>
  <keyword>Oral nutritional supplement (Food for special medical purposes)</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

